Why wait? The FDA stamps an ul­tra-fast OK on a HER2+ drug ex­pect­ed to cre­ate As­traZeneca's next block­buster fran­chise

The FDA isn’t play­ing any wait­ing games when it comes to hus­tling up a quick OK for a break­through can­cer drug.

In what has to be the fastest cul­mi­na­tion of one of the smoothest mul­ti-bil­lion dol­lar al­liances in bio­phar­ma his­to­ry, the agency stamped their seal of mar­ket­ing ap­proval on trastuzum­ab derux­te­can, a re­mark­able new drug now ready to mar­ket at As­traZeneca and their part­ners at Dai­ichi Sankyo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER